CA2384439A1 - Vecteurs adenoviraux modifies a utiliser en therapie genique - Google Patents
Vecteurs adenoviraux modifies a utiliser en therapie genique Download PDFInfo
- Publication number
- CA2384439A1 CA2384439A1 CA002384439A CA2384439A CA2384439A1 CA 2384439 A1 CA2384439 A1 CA 2384439A1 CA 002384439 A CA002384439 A CA 002384439A CA 2384439 A CA2384439 A CA 2384439A CA 2384439 A1 CA2384439 A1 CA 2384439A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- vector
- recombinant
- gene
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des moyens et des procédés de génération et de fabrication de vecteurs Ad recombinés qui sont modifiés dans des fonctions E2B et/ou E4. Ces vecteurs comportent de préférence des délétions E1 et/ou E2A. A cette fin, le génome du vecteur est modifié dans des régions du promoteur respectives, de façon que le promoteur soit uniquement actif dans une ligne cellulaire complémentaire adéquate ou suivant un certain signal dans le cas d'un promoteur inductible. Le promoteur modifié est, par ailleurs, inactif dans des conditions normales, et dans des cellules mammaliennes et/ou humaines. Ainsi, les vecteurs qui possèdent ce promoteur modifié dans la région E2B et/ou E4, n'expriment pas la région de transcription respective chez les mammifères et/ou les humains.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99202966.0 | 1999-09-10 | ||
EP99202966A EP1083229A1 (fr) | 1999-09-10 | 1999-09-10 | Vecteurs adénovirales modifiés pour la thérapie génique |
US15364199P | 1999-09-13 | 1999-09-13 | |
US60/153,641 | 1999-09-13 | ||
PCT/NL2000/000640 WO2001020014A1 (fr) | 1999-09-10 | 2000-09-11 | Vecteurs adenoviraux modifies a utiliser en therapie genique |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2384439A1 true CA2384439A1 (fr) | 2001-03-22 |
Family
ID=26153368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002384439A Abandoned CA2384439A1 (fr) | 1999-09-10 | 2000-09-11 | Vecteurs adenoviraux modifies a utiliser en therapie genique |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU7560500A (fr) |
CA (1) | CA2384439A1 (fr) |
WO (1) | WO2001020014A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007134325A2 (fr) * | 2006-05-15 | 2007-11-22 | Introgen Therapeutics, Inc. | Procédés et compositions pour la production de protéines à l'aide de vecteurs adénoviraux |
US20080089890A1 (en) * | 2006-09-29 | 2008-04-17 | Canji, Inc. | Methods of polypeptide production |
EP3945094A1 (fr) * | 2020-07-31 | 2022-02-02 | Heinrich-Pette-Institut | Adénovirus à réplication déficiente |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2333425T5 (es) * | 1995-06-15 | 2012-08-28 | Crucell Holland B.V. | Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica |
WO1997045550A2 (fr) * | 1996-05-31 | 1997-12-04 | Baxter International Inc. | Vecteur mini-adenoviral |
WO1998021350A1 (fr) * | 1996-11-13 | 1998-05-22 | Board Of Regents, The University Of Texas System | Diminution d'une expression genique virale par remplacement d'un promoteur |
US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
-
2000
- 2000-09-11 CA CA002384439A patent/CA2384439A1/fr not_active Abandoned
- 2000-09-11 WO PCT/NL2000/000640 patent/WO2001020014A1/fr active Application Filing
- 2000-09-11 AU AU75605/00A patent/AU7560500A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU7560500A (en) | 2001-04-17 |
WO2001020014A1 (fr) | 2001-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6878549B1 (en) | Packaging systems for human recombinant adenovirus to be used in gene therapy | |
US8236293B2 (en) | Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer | |
US6413776B1 (en) | High throughput screening of gene function using adenoviral libraries for functional genomics applications | |
US6228646B1 (en) | Helper-free, totally defective adenovirus for gene therapy | |
US7906113B2 (en) | Serotype of adenovirus and uses thereof | |
US20060003451A1 (en) | Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus | |
US20090098599A1 (en) | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use | |
SK156799A3 (en) | Method for the production of non-group c adenoviral vectors | |
CA2378061A1 (fr) | Systemes d'empaquetage pour adenovirus humains de recombinaison a utiliser en therapie genique | |
CA2318737A1 (fr) | Procedes de fabrication de vecteurs pseudo-adenoviraux | |
US20060246569A1 (en) | Packaging systems for human recombinant adenovirus to be used in gene therapy | |
CA2384439A1 (fr) | Vecteurs adenoviraux modifies a utiliser en therapie genique | |
EP1083229A1 (fr) | Vecteurs adénovirales modifiés pour la thérapie génique | |
EP1083228A1 (fr) | Vecteurs adénovirales modifiés pour la thérapie génique | |
US20030077828A1 (en) | Methods for highly efficient generation of adenoviral vectors | |
Seth et al. | Advantages and disadvantages of multiple different methods of adenoviral vector construction | |
CA2371069A1 (fr) | Systemes et procedes de transfert d'acide nucleique | |
US7585498B2 (en) | Regulation of adenovirus DNA packaging by IPTG | |
MXPA99011998A (en) | Generation of packaging system for human recombinant adenoviral vectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |